Figure 2.

LY3214996 enhanced sorafenib anti-proliferative effects in Huh7^R cells. (A) MTT assays detected cell viability of Huh7 and Huh7^R cells incubated with various concentrations of sorafenib for 24 h. (B) Cell viability of Huh7^R cells treated with sorafenib, LY3214996, and the combination after 24 h were assessed with MTT assays. (C) Cell viability of Huh7^R cells treated with sorafenib, LY3214996, or the combination for 12 h, 24 h, and 48 h determined with MTT assays. (D and E) Colony formation assays were used to determine the clonogenic capacity of Huh7^R cells treated with sorafenib, LY3214996, or a combination of the two. Data are expressed as mean ± SD of three independent experiments (*p<0.05; **p<0.01; ***p<0.001).